Can I take peptides with antidepressants?

Most strength peptides — BPC-157, TB-500, GHK-Cu, KPV, MOTS-c, the GH secretagogues, IGF-1 LR3 — have no documented interaction with SSRIs (sertraline, escitalopram, fluoxetine), SNRIs (venlafaxine, duloxetine), tricyclics, or other common antidepressants. The mechanisms don't overlap: peptides act on tissue-repair, GH-axis, or metabolic pathways; antidepressants act on serotonin, norepinephrine, and related CNS neurotransmitter systems.

The combination is generally safe, but you should tell the physician prescribing your antidepressant. Not because peptides will interfere with the SSRI, but because the prescriber should know about anything in your system that might affect mood, sleep, or how you experience the medication.

Why the interaction concern is low

Pharmacological interactions usually happen through one of three pathways:

1. Shared metabolic enzymes (mostly liver CYP450). Many drugs compete for the same enzymes; one drug can slow another's clearance.
2. Shared receptors or transporters. Two compounds binding the same target produce additive or competitive effects.
3. Downstream physiology overlap. Even with different mechanisms, drugs that both affect blood pressure, heart rate, or seizure threshold can stack.

Strength peptides don't significantly hit any of these for antidepressants:

• Liver metabolism: Most peptides are degraded by peptidases in the bloodstream and tissues, not by hepatic CYP450 enzymes. They don't compete with antidepressant metabolism.
• Neurotransmitter systems: Peptides like BPC-157 and TB-500 act on tissue-level repair, not central serotonin or norepinephrine. The CNS peptides (DSIP, Selank, Semax) have specific receptors that don't overlap with antidepressant targets.
• Downstream physiology: Most strength peptides don't materially affect heart rate, blood pressure, or seizure threshold at typical doses.

The CNS peptides — Selank, Semax, DSIP

The peptides that warrant slightly more caution alongside antidepressants are the CNS-active ones:

Selank — anxiolytic Russian peptide. Modest effects on GABAergic and serotonergic signaling. No documented adverse interaction with SSRIs, but layering anxiolytic effects on an SSRI may produce stronger sedation or mood blunting in some users. See Selank and Semax for athletes.

Semax — cognitive support peptide. Effects on BDNF and dopaminergic/serotonergic systems. Same caution as Selank.

DSIP — sleep architecture peptide. Pre-bed use is typical. Should not be combined with sedating antidepressants (trazodone, mirtazapine) without consideration — additive sedation is the concern. See DSIP for sleep architecture in athletes.

For these specifically, talk to your prescriber before starting.

Peptide-by-peptide quick reference

What can change subjectively

A few things sometimes shift when peptides are added on top of an antidepressant regimen, but these aren't interactions in the pharmacological sense — they're independent effects:

Sleep changes. GH-axis peptides (Ipamorelin, Sermorelin) often improve sleep quality. Users on SSRIs sometimes describe sleep as flatter or more fragmented; adding a GH peptide can shift that meaningfully. This is generally welcome.

Energy and mood. Better sleep, better recovery, and improved body composition can subtly improve mood. This isn't the peptide acting as an antidepressant — it's downstream effects of feeling physically better.

Side-effect overlap. Some antidepressants cause weight gain or appetite changes. MK-677 also produces hunger. The combination can make weight management harder.

Sexual side effects. SSRIs commonly cause sexual side effects. Peptides don't typically improve these, despite occasional marketing claims. PT-141 (Bremelanotide) is a separate peptide specifically for sexual function and operates on different pathways — and is outside the scope of this site.

The disclosure question

Should you tell your antidepressant prescriber that you're using peptides? Yes.

The conversation isn't about whether peptides interact with your antidepressant (they probably don't). It's about giving your prescriber accurate context for how you're feeling, whether your antidepressant dose is right, and whether any new symptoms you report might come from somewhere other than the SSRI.

Practical tips for that conversation:

• Bring the specific peptide names — "BPC-157" rather than "a peptide"
• Mention dose and timing
• Note any symptom shifts that started after the peptide began
• Don't expect your prescriber to be familiar with the specific peptide — they'll often need to look it up

For the broader doctor-disclosure framing see should I tell my doctor I'm using peptides?.

What to monitor

If you're starting a peptide while on an antidepressant, watch for:

• Sleep changes (usually improvements with GH peptides; rarely worsening)
• Mood shifts beyond your typical SSRI baseline
• Appetite changes (especially with MK-677)
• Any new symptoms that emerge in the first 2–4 weeks of the peptide

Track these so you can attribute correctly. Most users see no notable shift in their antidepressant experience from starting peptides. The few who do usually find the change is welcome (better sleep, better recovery) — but in either direction, knowing helps.

Related questions

• Should I tell my doctor I'm using peptides?
• Can I take peptides with thyroid medication?
• Peptides with metformin
• Selank and Semax for athletes